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Summary 
Bacterial  and retroviral superantigens (SAGs) interact with major histocompatibility complex 
(MHC) class II molecules and stimulate T cells upon binding to the V~3 portion of the T  cell 
receptor.  Whereas both types of molecules exert similar effects on T cells, they have very different 
primary structures. Amino acids critical for the binding of bacterial toxins to class II molecules 
have been identified  but little is known of the molecular interactions between class II and retroviral 
SAGs. To determine whether both types of superantigens interact with the same regions of MHC 
class II molecules, we have generated mutant HLA-DR molecules which have lost the capacity 
to bind three bacterial toxins (Staphylococcus aureus enterotoxin A  [SEA], S. aureus enterotoxin 
B [SEB], and toxic shock syndrome toxin 1 [TSST-1]).  Cells expressing these mutated class II 
molecules efficiently  presented two retroviral SAGs (Mtv-9 and Mtv-7) to T cells while they were 
unable to present the bacterial SAGs. These results demonstrate that the binding sites for both 
types of SAGs can be dissociated. 
S 
uperantigens (SAGs) bind to MHC class II molecules and 
stimulate a large proportion of T cells in a VB-restricted 
manner (1-3). Bacterial SAGs are soluble proteins that bind 
in an unprocessed form to class II molecules (4). The toxins 
produced by Staphylococcus aureus (S.  aureus enterotoxin A 
[SEA]; S. aureus enterotoxin B [SEB], and toxic shock syn- 
drome toxin 1 [TSST-1]) have been the most studied and are 
responsible for food poisoning and toxic shock syndrome (5). 
Although these SAGs have affinities in the nanomolar range 
for class II molecules (5),  mutation of a single residue on 
the oe or 3 chain of HLA-DR is sufficient to completely ab- 
rogate the binding of TSST-1  or SEA  (6-8).  In contrast, 
retroviral SAGs (known as minor lymphocyte stimulating an- 
tigens or Mls) encoded by the open reading frame (OR.F) 
in the 3' LTR of mouse mammary tumor viruses (MMTV) 
(9-12)  are type II transmembrane glycoproteins that likely 
encounter class II inside the cell (13, 14). Moreover,  the pri- 
mary sequences  of bacterial  and retroviral SAGs have  no 
significant homology (1,  3,  5).  Little is known about the 
interactions between retroviral SAGs and MHC class II mol- 
ecules,  except  that a hierarchy exists in the ability of the 
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different alleles and isotypes of human and murine class II 
molecules to present these SAGs (3,  5,  15). It is interesting 
to note that this hierarchy is not the same for the presenta- 
tion of bacterial SAGs (2, 5). These differences between the 
two types of SAGs have prompted us to investigate whether 
they interact with similar sites on MHC class II molecules. 
Extensive site-directed  mutagenesis studies have shown that 
only a few residues  on MHC class II molecules are critical 
for the binding of bacterial SAGs (6-8). We show that these 
mutations on MHC class II molecules abrogate the binding 
of SEA, SEB, or TSST-1 but do not impair the presentation 
of two retroviral SAGs (Mtv-7 and Mtv-9)  to T  cells. These 
results demonstrate that the binding sites for these two types 
of SAGs on MHC class II molecules can be dissociated. 
Materials and Methods 
Cell Lines.  The murine T cell hybridoma Kmls 13.11 expresses 
a TCR V~6 chain that allows recognition of Mtv-7 SAG but not 
of SEA and TSST-1 (16). 3DT52.5.8 (VB1  + and V~8.1 +) is a 
CD4- murine T cell hybridoma that recognizes  SEA and SEB but 
not Mtv-7 SAG (17). KTS-104.3 is a murine T cell hybridoma ex- 
pressing the TCR VB15 chain and is responsive to TSST-1. V/35#11 
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DAP-3 is an MHC class II negative murine fibroblastic cell line 
(18). The hybridomas Kmls13.11 and KTS-104.3 were grown in 
DME supplemented with 10% FCS (Gibco Laboratories, Grand 
Island, NY), 4 mM dextrose (Sigma Chemical Co., St. Louis, MO), 
2 mM L-glutamine, essential and nonessential amino acids, I mM 
sodium pyruvate (all from Gibco Laboratories), 10/xM 3-mercap- 
toethanol (Sigma Chemical Co.), and 20 #g/ml gentamycin (Gibco 
Laboratories). 3DT52.5.8 and V35#11 were grown in RPMI 1640 
(Gibco Laboratories) supplemented with 10% FCS, 2 mM r-gluta- 
mine, 10/~M 3-mercaptoethanol, and 20/~g/ml gentamycin.  DAP-3 
cells were cultured in DME supplemented with 5% FCS, 2 mM 
t-glutamine,  and 20/xg/ml gentamycin. 
Mutagenesis and Transfections.  Site-directed mutagenesis of the 
DILl o~ and 3 chain cDNAs was performed as previously described 
using the PCIL overlap extension technique (6). Mutated DILl 3 
chain cDNAs were subcloned in ILSV.3 vector and mutated DR 
c~ chain cDNA was subcloned in RSV.Sneo. The following muta- 
tions were introduced simultaneously  in the cr chain: K39A, V42A, 
and E46R (DILot 39.42.46). The mutated cDNAs  generated by 
PCIL were entirely sequenced. Stable transfections of wild-type or 
mutated MHC class II cDNAs were carried out using the calcium 
phosphate coprecipitation technique (19). Briefly,  DAP-3 cells  were 
cotransfected with 10/xg of wild-type or mutated MHC class II 
c~ and 3 chain cDNAs in the presence of  2/~g of pSV2neo carrying 
the neomycin resistance gene. Stable transfectants were selected in 
I mg/ml of G418 (Gibco Laboratories). Homogeneous populations 
of  DAP-3 cells expressing comparable levels of MHC class II mole- 
cules were obtained by aseptic cell sorting on a FACStar  |  Plus 
(Becton Dickinson Immunocytometry Systems, Mountain View, 
CA). MMTV sag genes cloned into the eukaryotic  expression  vector 
pH3-Aprl-neo (20), were stably transfected as described above. 
Transfected cells were selected in 1 mg/ml of G-418 or in 10 #g/ml 
of puromycin  (Sigma Chemical Co.).  Clones were picked after 
2 wk of selection and the remaining cells were kept as populations. 
For transient  transfections, the Mtv-7 sag, Mtv-9 sag, and B7 
cDNAs were subcloned into the R3CPy-II eukaryotic expression 
vector containing the polyoma origin of  replication (21). Transient 
transfections were performed using DEAE-dextran as described  (22). 
Briefly, 2  x  106 DR1, DILot 39.42.46, and DILl 81A cells were 
plated in 10-cm petri dishes 24 h before incubation in DME con- 
taining 0.4 mg/ml DEAE-dextran (Pharmacia, Uppsala, Sweden), 
10% Nuserum (Collaborative Research Incorporated,  Waltham, 
MA) and 20/zg of  DNA for 4 h at 37~  Cells were then incubated 
in PBS-10% DMSO for 2 min and washed two times with DME 
without serum. Cells were kept in culture for 2 d, stained for class 
II expression and used in functional assays. Parallel transfections 
using the B7 cDNA confirmed the reproducibility of this assay. 
Cytofluorometric Analysis of  DAP-3 Cells Transfected  with HLA-DR 
Molecules.  Cells were  stained  with  L-243 or  50D6,  a  mouse 
anti-human MHC class II antibody which recognizes all DR al- 
leles except DR7 and DILw53, followed by GAM-FITC. As nega- 
tive control, the different transfectants were stained with the sec- 
ondary antibody alone. MHC class II expression was analyzed by 
flow cytometry  using a FACScan  |  (Becton Dickinson Immunocyto- 
metry Systems). 
Northern Blot  Analysis.  RNA  was  isolated using  RNAzol 
(Cinna/Biotecx Laboratories, Friendswood, TX). 20/zg of ILNA 
were separated on a 1.2% agarose-formaldehyde gel (23), trans- 
ferred to a nylon membrane (Amersham Corporation,  Oakville, 
Ontario, Canada), and hybridized at 42~  in 50% formamide with 
Mtv-7 sag and histone H3 cDNA (24) probes at the same time. 
The blot was washed at 65~  for 30 min in 2x  SSC and exposed 
on a phosphorimager screen (Molecular  Dynamics, Inc., Sunnyvale, 
CA) and then on Kodak XAIL-5 film. Ratios of MMTV sag to 
histone H3 miLNAs were calculated using the Imagequant soft- 
ware (Molecular Dynamics, Inc.). 
T Cell Stimulation.  Stimulation ofT cell hybridomas with SEA, 
SEB, and TSST-1 (Toxin  Technology Inc., Sarasota, FL) was car- 
fled out as follows: 75  x  103 T cells/well were added to 2  x  104 
DAP-3 fibroblasts  expressing  wild-type or mutated HLA-DR1 mol- 
ecules with various concentrations of  bacterial toxins (0-10 #g/ml). 
Presentation of MMTV SAGs by mutated MHC class II molecules 
was performed as follows: DAP-3 cells expressing MHC class II 
molecules were stably or transiently transfected with MMTV sag 
gene and cocultured in the presence of 6  x  104 MMTV SAG- 
reactive murine T cell hybridomas at different stimulator/effector 
ratios (1:1, 1:3, and 1:10). All the cocultures were done in a final 
volume of 200/A in 96-well flat bottom plates for 18 h at 37~ 
5% CO2. 
IL-2 Production Measurements.  IL-2 production was determined 
by the ability of the coculture supernatants to support the prolifer- 
ation of the IL-2-dependent  cell line CTLL.2 using the hexosa- 
minidase colorimetric assay (25). A calibration curve using recom- 
binant human IL-2 (Cetus Corp.,  Berkeley, CA) was performed 
in parallel. 
Results and Discussion 
With the knowledge that bacterial and retroviral SAGs have 
different primary structures,  we tested the possibility that 
their binding sites on MHC class II molecules are separable. 
For this purpose, we generated DR1 mutants that do not 
bind the bacterial toxins SEA, SEB, and TSST-1. As illus- 
trated in Fig.  1 A,  the substitution of histidine 81 in the 
DR3 chain by an alanine (DAP DR1 81A) abolishes presen- 
tation of SEA to the 3DT52.5.8 T cell hybridoma confirming 
previously published results (6, 7). Control cells expressing 
either wild-type DR1 or DR1 mutated at positions 39, 42, 
and 46 in the ot chain (DAP DRo~ 39.42.46) efficiently stimu- 
lated 3DT52.5.8 in the presence of increasing concentrations 
of SEA (Fig.  1 A).  Cells expressing DRot 39.42.46 could 
not present SEB (Fig.  1 B) or TSST-1 (Fig.  1 C) to T cells, 
whereas  the  control  DR1  and  DR1  81A  transfectants 
efficiently  presented both toxins. This inability to present SEB 
and TSST-1 is due to a lack of binding of these toxins to 
MHC class II molecules (not shown).  Lysine 39 on DRcr 
had already been shown to be critical for binding and presen- 
tation of TSST-1 (8). These results indicate that TSST-1 and 
SEB binding sites are in close proximity (Thibodeau, J., N. 
Labrecque, and R.-P.  S~kaly, manuscript in preparation). 
Cells expressing class II molecules that fail to present SEA, 
SEB, and TSST-1 were transfected with Mtv-7 sag and ana- 
lyzed for their ability to stimulate T  cells.  The Kmlsl3.11 
hybridoma responded efficiently to DR1 mtv7 cells but not 
to control DR1 mtv9 or DR1 cells (Fig. 2 A). Cells expressing 
DRot 39.42.46,  which can not present SEB  and TSST-1, 
efficiently presented the Mtv-7 SAG to this hybridoma even 
at the lowest dilution of APCs. Moreover, DR1  81A cells 
which fail to bind or present SEA (Fig. 1 A), stimulated Kmls 
13.11 cells when transfected with the Mtv-7 sag. Similar results 
were obtained using a V3 8.1 + and another V3 6 + Mtv-7 
SAG-reactive T cell hybridoma (not shown). Fluctuations in 
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Figure  1.  SEA, SEB, and TSST-1 presentation  to T cells by HLA-DR 
mutants.  (.,t) SEA presentation  is abolished by mutation of residue B81 
of HLA-DR1. Dose-response  curve of SEA presented by DAP-3 cells ex- 
pressing wild-type DILl (DAP DILl or DAP DILl med which expresses 
lower levels of class II), DILa 39.42.46,  and DILl 81A to the mufine T 
cell hybridoma  3DT52.58.  (B) Mutations at residues 39,  42,  and 46 of 
HLA-DRa chain abrogate SEB presentation to T cells. Dose-response curve 
of SEB presented to 3DT52.5.8  by APCs expressing DR1 or DR1 med, 
DRcx 39.42.46,  and DR1 81A. (C) TSST-1 presentation  is abolished by 
mutation of HLA DILa chain residues 39, 42, and 46. Dose-response curve 
of TSST-1 presented  to the murine T cell hybridoma  KTS-104.3 by un- 
transfected DAP-3 ceils, DAP DILl, DAP DILl med, DAP DiLo139.42.46, 
and DAP DILl 81A. M.F.V. of class II expression using 50D6 mAb were 
DAP DILl, 125; DR1 med, 7; DAP DRa 39.42.46,  74; and DAP DILl 
81A, 73. 
Figure 2.  Presentation  of Mtv-7 SAG by mutant MHC class II mole- 
cules. (A) DAP-3 cells expressing wild-type or mutated class II molecules 
were stably transfected with MW-7  sag and used as APCs at different stimu- 
lator/effector ratios (1:1, 1:3, 1:10) for the stimulation of Kmls13.11 T cell 
hybridoma.  Populations of cells were used except for DRa 39.42.46B and 
DR1 81A which have been cloned from the Mtv-7 transfected population. 
Untransfected  DR1 cells or transfected with Mtv-9 sag were used as nega- 
tive controls. M.F.V. of class II expression as determined using 50I:)6 mAb 
is indicated  on top of each histogram.  (B) Northern blot showing the 
levels of Mtv-7 sag and histone H3 mRNA in the different transfectants. 
The ratio of Mtv-7 sag to histone H3 mRNA is indicated below each lane. 
(C) Stimulation  of Kmls13.11 using DAP DR1 mutants transiently trans- 
fected with Mtv-7 sag. DILl cells transfected  with Mtv-9 sag were used 
as negative control in the stimulation assays. Parallel transfections  using 
the B7 cDNA showed that 40-50% of the cells expressed B7 with a mean 
fluorescence value (M.EV.) of 300.  M.F.V. of class II expression on the 
different transfectants  was determined  using the 50D6 mAb and is indi- 
cated on top of each histogram. 
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cules. (A) DAP-3 cells expressing  DK1, DRo~ 39.42.46, DILl 81A, or 
DR1 81Y were stably transfected  with Mtv-9 sag DNA and used as APCs 
to stimulate VB5#11 T cell hybridoma  (V~5  +). Populations  were used 
except for DRcr 39.42.46A which has been cloned  from the puromycin 
resistant population. DAP cells expressing  DR1 alone  or DR1 plus  Mtv-7 
SAG were used as negative  controls. M.F.V. of class II expression  on the 
different transfectants  as determined  using 50D6 mAb is indicated on top 
of each histogram. (B) The levels of Mtv-9 sag and histone H3 mRNA 
in the different  transfectants  is shown. Northern blot analysis was carried 
out using the homologous  Mtv-7 sag probe. The ratio of Mtv-9 mRNA 
as compared  with histone H3 mRNA is indicated  for each transfectant. 
(C) Stimulation of V/85#11 T cell hybridoma using DAP DR1, DAP 
DRc~39.42.46, and DAP DR1 81A transfected  transiently  with Mtv-9 sag. 
Control transfections  using B7 cDNA showed that 20-30% of the cells 
expressed B7 with a M.F.V. of 200-400 (data not shown). M.F.V. of class 
II expression  are indicated on top of each bar and was determined  using 
50D6 mAb. 
levels of T cell stimulation were correlated to levels of Mtv-7 
sag transcripts, as determined by Northern blot analysis (Fig. 
2 B) and to class II levels, as monitored by flow cytometry 
(Fig.  2 A). 
To minimize clonal variations,  a transient transfection assay 
was used. Control transfections using the B7 cDNA reprodu- 
cibly gave 40-50% of positive cells (not shown). DR1 cells 
~ransiently transfected with the Mtv-7 sag stimulated the Kmls 
13.11 hybridoma (Fig. 2 C) whereas no response was observed 
with control DR1  cells  transiently transfected with Mtv-9 
sag. Cells expressing mutant class II molecules that did not 
present SEA (DR1 81A) or SEB and TSST-1 (DRo~ 39.42.46) 
stimulated Kmls13.11  after transient transfection with  the 
Mtv-7 sag at all ratios of cells used (Fig.  2 C). These results 
show that mutation of the residues critical for the binding 
of bacterial toxins have no effect on the presentation of the 
Mtv-7 SAG. 
These observations were extended to another retroviral SAG 
(Mtv-9). Fig. 3 A shows that comparable levels of IL-2 produc- 
tion were obtained when the T cell hybridoma V~5#11 was 
cultured with cells expressing Mtv-9 SAG and wild-type (DR1) 
or mutant (DR1 81A,  DR1 81Y, and DtLor 39.42.46) class 
II molecules (Fig.  3 B). These results were confirmed using 
the transient transfection assay (Fig.  3 C). Cells expressing 
wild-type or mutated DR.1 were capable of presenting Mtv-9 
SAG, whereas control DR1 cells transfected with Mtv-7 sag 
failed  to stimulate  this  hybridoma. 
These results demonstrate that the residues that are crit- 
ical  for the binding of bacterial SAGs are not essential  for 
the presentation of two different retroviral SAGs, Mtv-7 and 
Mtv-9. On the basis of the mutations we have performed on 
MHC class II molecules, it is clear that the binding sites of 
both types of SAGs can be dissociated. This is not surprising 
since bacterial SAGs like SEA and SEB, which share strong 
homologies in their amino acid sequences (1, 5) and have a 
proposed similar three-dimensional structure (26), bind to 
different sites on MHC class II molecules (Fig.  1) (6-8, 27). 
Moreover, the hierarchy observed in the presentation of bac- 
terial and retroviral SAGs by aUelic and isotypic forms of class 
II molecules is different. Bacterial SAGs are efficiently presented 
by I-A, I-E, DR, and DQ, whereas I-E and DR are the most 
potent class II molecules for presentation of retroviral SAGs 
(3, 5,  15).  We have recently shown that several DR alleles 
that can efficiently present SEA, SEB,  or TSST-1 (DR2a, 
DR2b, DRw53) fail to present Mtv-7 sag to T  cells, further 
confirming that these two types of SAGs interact differently 
with MHC class II molecules (15, 28). Tortes et al. have re- 
cently reported that bacterial SAGs and the peptide 76-119 
derived from Mtv-1  SAG  (ORF  peptide) can compete for 
binding to class II, indicating that both types of SAGs share 
a common binding region (29). The peptide used in these 
competition experiments contains three putative glycosyla- 
tion sites that are conserved in MMTV SAGs (13,  14). The 
use of such peptide might not reflect the natural interactions 
between MHC class II and retroviral SAGs. It is likely how- 
ever that many regions are involved in the binding of retroviral 
SAGs to MHC class II molecules.  Single point mutations may 
1032  Binding  Sites for Superantigens Can Be Dissociated not be sufficient to abrogate the interaction between these 
two molecules. 
Results presented in this paper and others (6-8) have clearly 
demonstrated that SAGs (retroviral and bacterial) can interact 
with class II in many distinct ways and still stimulate T  cells 
in a VB restricted fashion.  Selective pressures  must  act on 
pathogens  to code for SAGs that bind to different regions 
on class II in order to avoid competition with other endoge- 
nous  or exogenous molecules. 
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